Trial Profile
Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: A randomized, double-blind, placebo-controlled trial in Canadian women
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Paroxetine (Primary)
- Indications Premenstrual dysphoric disorder
- Focus Therapeutic Use
- 01 Jun 2008 Results have been published in Journal of Clinical Psychiatry.
- 26 Mar 2008 New trial record.